We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Emisphere Technologies, Inc announced that it has entered into a multi-product research collaboration agreement with Roche to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of a number of Roche molecules.
King Pharmaceuticals, Inc. announced that the U.S. District Court for the Eastern District of Virginia, Norfolk Division, upheld the validity of U.S. Patent No. 5,061,722 (the "722 patent"), the composition of matter patent covering Altace (ramipril).
MedImmune Inc. announced that it received complete response letter from the U.S. Food and Drug Administration for a supplemental biologics license application related to the new formulation of FluMist, the intranasal flu vaccine.
Watson Pharmaceuticals and Andrx have extended their merger deadline an additional two months to address the FTC's review of the transaction, the companies said.
Sen. Chuck Grassley (R-Iowa), a frequent critic of the FDA's drug safety policies, is turning his sights toward drug compounding in an effort to address allegations of fraud and safety concerns.
RxUSA Wholesale Inc. announced the filing, in the Eastern District of New York, of a Complaint, DOCKET # 06 CV 3447, seeking recovery of damages in the amount of $586,733,225.00, and in addition, the recovery of three-fold damages ($1,760,199,675.00), together with reasonable attorneys' fees incurred by Plaintiff, and the costs of the action.